复牌！跨界半导体，重大资产重组来了

Group 1 - The core point of the news is that Sunflower will resume trading on September 22, 2025, after a suspension for a major asset restructuring [1] - Sunflower's stock experienced significant price increases prior to the suspension, with a rise of 15.83% on August 29 and 11.96% on September 5, leading to a market capitalization of 6.38 billion yuan as of September 5 [1] Group 2 - The major asset restructuring involves Sunflower acquiring 100% of Xipu Materials and 40% of Beid Pharmaceutical through a combination of share issuance and cash payment, with plans to raise additional funds [2] - Xipu Materials focuses on high-end semiconductor materials, with projected revenues of 38.54 million yuan in 2023 and 98.54 million yuan in 2024, and net profits of 0.0408 million yuan and 1.37652 million yuan respectively [2] - This transaction will allow Sunflower to enter the high-end semiconductor materials sector, creating a second growth curve for the company [2] Group 3 - Morgan Stanley increased its holdings in Sunflower by 724,800 shares, bringing its total to 6.4255 million shares, which represents 0.5% of the company [3] - Following the acquisition of a 60% stake in Beid Pharmaceutical, Sunflower divested its traditional photovoltaic business to focus on the pharmaceutical sector [3] - Sunflower's net profit has shown a declining trend from 2020 to 2024, with figures of 56 million yuan, 53 million yuan, -1.1387 million yuan, 22 million yuan, and 7.8273 million yuan [3] - In the first half of 2025, Sunflower reported revenue of 144 million yuan, a year-on-year decrease of 8.33%, and a net profit of 1.1607 million yuan, down 35.68% year-on-year [3]